Emergent BioSolutions Reports Second Quarter 2026 Financial Results
Emergent BioSolutions reported Q2 2026 revenue of $234.3 million, up 66% year-over-year and significantly exceeding guidance, driven by accelerated government contract modifications for medical countermeasures. However, the company recorded a non-cash impairment charge of $191.3 million related to its NARCAN assets, resulting in a GAAP net loss of $180.2 million for the quarter.
Key figures
- Revenue
- 234300000
- Guidance
- FY26 Total Revenues $645 - $675 million (down from $720 - $760 million); Adjusted Net Income $10 - $30 million (down from $45 - $65 million)
- Revenue Yoy
- 66%
- Adjusted ebitda
- 96500000
- Gross margin pct
- 50%
- Impairment charge
- 191300000
- Adjusted net income
- 30900000
- Restructuring savings
- 40000000
- Adjusted gross margin pct
- 58%
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.